April 28 - May 1, 2019Oegstgeest (near Leiden), The Netherlands
This intensive course is intended for scientists working in the field, and the presentations will be given by senior scientists from industry and academia. The number of participants is limited to 35, to allow in depth discussion. Should the number of applications exceed the maximum, preference will be given to applicants from EFMC adhering countries and employees of EFMC corporate members. Upon special request to the organisers, only based on financial conditions and supported by an argued recommendation of the head of the department of the applicant, up to 3 applicants from academia may be admitted at a reduced fee.
In the last twenty years, FBDD has proven to be an effective approach for hit identification for chemical biology and drug discovery projects with many fragment-derived compounds now in clinical trials and a few on the market. This course will provide an introduction for medicinal chemists to the important concepts and methods, including fragment libraries, fragment screening technologies and relevant computer-aided drug design approaches. The course will finish with a series of presentations on applications of FBDD, including summaries of published fragment to lead optimisation strategies. The course will be organized by the FRAGNET consortium, a European training network dedicated to FBDD.
- Dr Xavier BARRIL (GAIN THERAPEUTICS, Mataro)
- Dr Ben DAVIS (VERNALIS PLC, Cambridge, United Kingdom)
- Dr Paul ENGLAND (IOTA PHARMACEUTICALS LTD., Cambridge, United Kingdom)
- Dr Mike HANN (GLAXOSMITHKLINE, Stevenage, United Kingdom)
- Prof. Rod HUBBARD (UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom)
- Prof. Gyorgy KESERU (RESEARCH CENTRE FOR NATURAL SCIENCES, HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)
- Prof. dr. Gregg SIEGAL (Zobio, Leiden, Nehterlands)
Organised by: Iwan DE ESCH (VU University Amsterdam, The Netherlands) and Henk TIMMERMAN (VU University Amsterdam, The Netherlands)